Ibrutinib in Refractory or Relapsing Primary Central Nervous System Lymphoma: A Systematic Review

Area of Science:

• Oncology
• Neurology
• Hematology

Background:

• Primary Central Nervous System Lymphoma (PCNSL) is a rare Non-Hodgkin Lymphoma (NHL) subtype.
• PCNSL affects the brain, spinal cord, leptomeninges, or eyes.
• Standard treatments often lead to relapses or refractoriness, with poor prognosis for R/R PCNSL.

Purpose of the Study:

• To systematically review and critically appraise the evidence on ibrutinib's efficacy.
• To evaluate ibrutinib as a novel treatment for Refractory or Relapsed (R/R) PCNSL.

Main Methods:

• Systematic review of studies on ibrutinib for R/R PCNSL.
• Critical appraisal of existing evidence regarding treatment efficacy.

Main Results:

• Preliminary studies suggest promising results for ibrutinib in R/R PCNSL.
• Evidence is based on limited sample sizes, requiring further investigation.

Conclusions:

• Ibrutinib demonstrates potential as a treatment option for R/R PCNSL.
• Further research with larger cohorts is needed to confirm efficacy and optimal use.